Sector News

Australia’s CSL buys Novartis flu vaccine unit for $275 mln

October 27, 2014
Life sciences
(Reuters) – Australia’s CSL Ltd , the world’s largest blood products company, said on Monday it had agreed to buy Novartis AG’s global influenza vaccine business for $275 million, part of the Swiss drugmaker’s drive to focus on its best assets.
 
The sale of the flu business will conclude Novartis’ overhaul of its units which it had flagged in April, aimed at strengthening its cancer business and exiting underperforming operations.
 
Novartis said in April GlaxoSmithKline was buying its vaccines business, excluding flu, for $5.25 billion plus potential milestone payments of up to $1.8 billion and royalties.
 
The sale of its flu business to CSL will trigger an exceptional pretax impairment charge of approximately $1.1 billion, as the selling price is below the book value of the assets, Novartis said in a statement on Monday.
 
The charge will be excluded from the Swiss drugmaker’s core results and a one-time operating income gain expected from the deal with GSK will compensate for the charge, it said.
 
Combining the Novartis unit with CSL subsidiary bioCSL would create the No.2 player in the $4 billion global influenza vaccine industry, CSL said in a statement to the Australian stock exchange.
 
CSL, which said it would fund the deal with surplus cash, estimated integration costs at $100 million, while synergy benefits were seen at $75 million a year by 2020.
 
The deal is expected to close in the second half of 2015, pending regulatory approval, Novartis said. (Reporting by Lincoln Feast in Sydney and Alice Baghdjian in Zurich; Editing by Robin Pomeroy and David Holmes)

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach